Open Nav

Ramesh Kumar


Onconova Therapeutics, Inc.

Dr. Kumar co-founded Onconova in 1998. He received his Ph.D. in Molecular Biology from the University of Illinois, Chicago, and trained at the National Cancer Institute. He has held positions in R&D or management at Princeton University, Bristol-Myers Squibb, DNX (later Nextran, a subsidiary of Baxter) and Kimeragen (later Valigen), where he was President of the Genomics and Transgenics Division. Dr. Kumar has more than 50 publications spanning molecular oncology, transgenic animals, gene therapy and recombination. He is an inventor in eight U.S. patents and many patent applications. He co-edited the 1993 book "Molecular Basis of Human Cancer."

This speaker's sessions: